Literature DB >> 19344863

The search for protection against HIV infection.

Roger Detels1.   

Abstract

More than 25 years after the recognition of AIDS and the isolation of the causative agent, human immunodeficiency virus (HIV), we have been unable to develop a vaccine to protect against infection. The major obstacle to development of a vaccine has been the absence of naturally acquired protective immunity, which is characteristic of most infectious agents. We and others, however, have identified individuals who appear to be resistant to infection. Using a combination of epidemiology, molecular biology, and genetics, we hypothesize that these individuals are able to resist infection by clearing low doses of HIV from their systems. We further hypothesize that they are able to clear the virus through a highly efficient system of processing and presentation of HIV epitopes (antigens) to CD8+ cytotoxic cells, which activate them to remove virally infected cells. Subsequent studies have lent support to this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344863      PMCID: PMC2767230          DOI: 10.1016/j.annepidem.2009.01.007

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  9 in total

1.  Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.

Authors:  P A Zimmerman; A Buckler-White; G Alkhatib; T Spalding; J Kubofcik; C Combadiere; D Weissman; O Cohen; A Rubbert; G Lam; M Vaccarezza; P E Kennedy; V Kumaraswami; J V Giorgi; R Detels; J Hunter; M Chopek; E A Berger; A S Fauci; T B Nutman; P M Murphy
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  HIV vaccine failure prompts Merck to halt trial.

Authors: 
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

3.  Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.

Authors:  D T Imagawa; M H Lee; S M Wolinsky; K Sano; F Morales; S Kwok; J J Sninsky; P G Nishanian; J Giorgi; J L Fahey
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

4.  Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.

Authors:  J Townsley-Fuchs; L Kam; R Fairhurst; S J Gange; L Goodglick; J V Giorgi; N Sidell; R Detels; J Braun
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

Authors:  J A Berzofsky; C D Pendleton; M Clerici; J Ahlers; D R Lucey; S D Putney; G M Shearer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

Authors:  S L Rowland-Jones; T Dong; K R Fowke; J Kimani; P Krausa; H Newell; T Blanchard; K Ariyoshi; J Oyugi; E Ngugi; J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

7.  T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners.

Authors:  A Ranki; S Mattinen; R Yarchoan; S Broder; J Ghrayeb; J Lähdevirta; K Krohn
Journal:  AIDS       Date:  1989-02       Impact factor: 4.177

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  A whole-genome association study of major determinants for host control of HIV-1.

Authors:  Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein
Journal:  Science       Date:  2007-07-19       Impact factor: 47.728

  9 in total
  2 in total

1.  Molecular docking of (5E)-3-(2-aminoethyl)-5-(2- thienylmethylene)-1, 3-thiazolidine-2, 4-dione on HIV-1 reverse transcriptase: novel drug acting on enzyme.

Authors:  Chandrabhan Seniya; Ajay Yadav; Kuldeep Uchadia; Sanjay Kumar; Nitin Sagar; Priyanka Shrivastava; Shilpi Shrivastava; Gulshan Wadhwa
Journal:  Bioinformation       Date:  2012-07-21

2.  HIV-1 Tat Binding to PCAF Bromodomain: Structural Determinants from Computational Methods.

Authors:  Vo Cam Quy; Sergio Pantano; Giulia Rossetti; Mauro Giacca; Paolo Carloni
Journal:  Biology (Basel)       Date:  2012-08-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.